Patient distribution in 3 classes of standardized values around the mean value for all anticoagulant drugs (0) assessed at C-trough or at C-peak, with the number of patients and of bleeding complications recorded in each class. The equivalent DOAC plasma levels for each class are also reported
| C-trough . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes of standardized C-trough values . | Equivalent DOAC C-trough plasma levels (ng/mL) . | Patients, n . | Follow-up, y . | Bleeding complication, n . | Incidence, % pt/yrs (95% CI) . | ||||||
| Apixaban . | Edoxaban . | Rivaroxaban . | Dabigatran . | ||||||||
| 2.5 mg/BID . | 5 mg/BID . | 30 mg . | 60 mg . | 20 mg . | 110 mg/BID . | 150 mg/BID . | |||||
| ≤ −0.50 (low levels) | ≤77 | ≤94 | ≤23 | ≤24 | ≤22 | ≤78 | ≤68 | 531 | 513 | 15 | 2.92 (1.7-4.8) |
| −0.49 to 0.50 (intermediate levels) | 78-146 | 95-160 | 24-54 | 25-58 | 23-52 | 81-138 | 69-128 | 804 | 790 | 20 | 2.53 (1.6-3.9) |
| > 0.50 (high levels) | >149 | >163 | >55 | >60 | >53 | >143 | >132 | 322 | 302 | 15 | 4.97 (2.8-8.2) |
| --- | --- | --- | --- | --- | --- | --- | 1657 | 1605 | 50 | 3.11 (2.3-4.1) | |
| C-trough . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes of standardized C-trough values . | Equivalent DOAC C-trough plasma levels (ng/mL) . | Patients, n . | Follow-up, y . | Bleeding complication, n . | Incidence, % pt/yrs (95% CI) . | ||||||
| Apixaban . | Edoxaban . | Rivaroxaban . | Dabigatran . | ||||||||
| 2.5 mg/BID . | 5 mg/BID . | 30 mg . | 60 mg . | 20 mg . | 110 mg/BID . | 150 mg/BID . | |||||
| ≤ −0.50 (low levels) | ≤77 | ≤94 | ≤23 | ≤24 | ≤22 | ≤78 | ≤68 | 531 | 513 | 15 | 2.92 (1.7-4.8) |
| −0.49 to 0.50 (intermediate levels) | 78-146 | 95-160 | 24-54 | 25-58 | 23-52 | 81-138 | 69-128 | 804 | 790 | 20 | 2.53 (1.6-3.9) |
| > 0.50 (high levels) | >149 | >163 | >55 | >60 | >53 | >143 | >132 | 322 | 302 | 15 | 4.97 (2.8-8.2) |
| --- | --- | --- | --- | --- | --- | --- | 1657 | 1605 | 50 | 3.11 (2.3-4.1) | |
| C-Peak . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes of standardized C-peak values . | Equivalent DOAC C-peak plasma levels (ng/mL) . | Patients, n . | Follow-up, y . | Bleeding complication, n . | Incidence, % pt/yrs (95% CI) . | ||||||
| Apixaban . | Edoxaban . | Rivaroxaban . | Dabigatran . | ||||||||
| 2.5 mg/BID . | 5 mg/BID . | 30 mg . | 60 mg . | 20 mg . | 110 mg/BID . | 150 mg/BID . | |||||
| ≤ −0.50 (low levels) | ≤189 | ≤202 | ≤149 | ≤197 | ≤165 | ≤172 | ≤159 | 454 | 443 | 14 | 3.16 (1.7-5.3) |
| −0.49 to 0.50 (intermediate levels) | 191-294 | 203-291 | 151-232 | 205-309 | 166-260 | 173-277 | 165-248 | 476 | 457 | 14 | 3.06 (1.7-5.1) |
| > 0.50 (high levels) | >304 | >297 | >233 | >310 | >268 | >279 | >267 | 368 | 360 | 11 | 3.06 (1.5-5.5) |
| --- | --- | --- | --- | --- | --- | --- | 1298 | 1298 | 39 | 3.09 (2.2-4.2) | |
| C-Peak . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes of standardized C-peak values . | Equivalent DOAC C-peak plasma levels (ng/mL) . | Patients, n . | Follow-up, y . | Bleeding complication, n . | Incidence, % pt/yrs (95% CI) . | ||||||
| Apixaban . | Edoxaban . | Rivaroxaban . | Dabigatran . | ||||||||
| 2.5 mg/BID . | 5 mg/BID . | 30 mg . | 60 mg . | 20 mg . | 110 mg/BID . | 150 mg/BID . | |||||
| ≤ −0.50 (low levels) | ≤189 | ≤202 | ≤149 | ≤197 | ≤165 | ≤172 | ≤159 | 454 | 443 | 14 | 3.16 (1.7-5.3) |
| −0.49 to 0.50 (intermediate levels) | 191-294 | 203-291 | 151-232 | 205-309 | 166-260 | 173-277 | 165-248 | 476 | 457 | 14 | 3.06 (1.7-5.1) |
| > 0.50 (high levels) | >304 | >297 | >233 | >310 | >268 | >279 | >267 | 368 | 360 | 11 | 3.06 (1.5-5.5) |
| --- | --- | --- | --- | --- | --- | --- | 1298 | 1298 | 39 | 3.09 (2.2-4.2) | |
CI, confidence interval; pt/y, patient/years.